Market Cap | 14.87M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -3.58M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 25.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 1.66 | EPS next 5Y | - | 52W High Chg | -83.00% |
Recommedations | 3.00 | Quick Ratio | 34.75 | Shares Outstanding | 4.46M | 52W Low Chg | 96.00% |
Insider Own | 35.48% | ROA | -28.86% | Shares Float | 3.18M | Beta | 1.68 |
Inst Own | 4.43% | ROE | -51.80% | Shares Shorted/Prior | 105.85K/72.69K | Price | 3.94 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 113,989 | Target Price | - |
Oper. Margin | - | Earnings Date | - | Volume | 117,642 | Change | 0.25% |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.